NCT05387668View on ClinicalTrials.gov

Safety, Tolerability, and Pharmacokinetics of BGB-23339 in Healthy Japanese and Caucasian Subjects

PHASE1WithdrawnINTERVENTIONAL

0

Timeline

Start Date

February 17, 2022

Primary Completion Date

October 17, 2022

Study Completion Date

October 17, 2022

Conditions

Healthy Volunteers

Interventions

DRUG

BGB-23339

Administered orally as a tablet.

DRUG

Placebo

Administered orally as a tablet.

Trial Locations (1)

89113

PPD, Las Vegas

Sponsors

Lead Sponsor

All Listed Sponsors

lead

BeiGene

INDUSTRY